CTLA4 and neoplasm: As this study provides proof-of-principle that Tregs impair anti-tumor immunity in the context neoadjuvant ICB, it will be crucial to identify how the variety of immunomodulatory drugs that are in clinical development will affect Treg activation beyond anti-PD-1 and anti-CTLA-4.